Summary One hundred large bowel carcinomas operated on between 1978 and 1982 were studied immunohistochemically with regard to expression of HLA-DR antigens. Three sections from each tumour were investigated by a semiquantitative scoring system, and a mean score for each patient established. Based on this scoring system, the tumours were divided into three groups: 0; 0.1 -1.0; and > 1.0. All patients were followed until death (n = 68) or until June 1, 1992, and all cancer-specific deaths (n = 56) have been recorded. Analysis of survival in the whole patient group showed significant difference between the three levels of tumour HLA-DR expression (P = 0.006); patients who had tumours with strong HLA-DR expression showing the best survival. In a stratified analysis after Dukes' stages there was still a significant difference (P>0.001) between the three levels of HLA-DR staining intensity. After a multiple regression analysis (Cox) with correction for different variables, the HLA-DR expression maintained its significance as a risk factor. To our knowledge this is the first time a relationship between intensity of tumour DR expression and survival has been shown in large bowel carcinoma.
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Several attempts have been made to define histopathological characteristics of prognostic significance for patients with large bowel carcinoma. A positive correlation between histological tumour grade and survival time has been reported (Remmele & Heine, 1981) , but up to now, staging has been considered the most reliable way to assess prognosis (Dukes & Bussey, 1958; Turnbull et al., 1967; Remmele & Heine, 1981 ). The preoperative plasma CEA level has proved valuable in follow-up studies after surgery for large bowel carcinomas (Wanebo et al., 1978; Rognum, 1986; Meling et al., 1992) . During the last years several papers applying flow cytometric DNA determination methods in human solid tumours have been published, and studies have shown that the presence of distinctly aneuploid DNA ploidy pattern in large bowel carcinoma worsens survival rates significantly (Wolley et al., 1982; Rognum et al., 1987a Rognum et al., , 1991 .
HLA class II antigen expression has recently been related to good prognosis in squamous cell carcinoma of the larynx (Esteban et al., 1990 ) and breast carcinoma (Concha et al., 1991) , whereas HLA-DR positivity was related to a bad prognosis in malignant melanoma (Zaloudik et al., 1988) . In large bowel carcinomas the association between HLA-DR expression and prognosis is less clear, since Gutierrez et al. (1987) found a correlation between DR-expression and prognosis according to Jass's stages (Jass et al., 1986 (Jass et al., ), while M6ller et al. (1991 did not find any influence of HLA-DR on disease-free survival.
The purpose of the present study was to test a possible prognostic significance of tumour DR-expression in 100 large bowel carcinomas with at least 10 years postoperative observation time.
Patients, materials and methods
Patients
One hundred large bowel carcinomas from 100 patients operated on between 1978 and 1982 were studied immunohistochemically with regard to expression of HLA-DR antigens. The mean age of the patients was 64.5 years (range 28 to 89 years), and there were 52 men and 48 women. All tumours were staged according to the extended Dukes' scheme, which (Turnbull et al., 1967) . The tumours were in addition graded as well-, moderately-, or poorly differentiated (Ashley, 1978) . Gross pathological examination was performed by the same observer (T.O.R.) throughout the study. The distribution of the variables is given in Table I .
Immunohistochemistry
Tissue slices from each tumour were fixed in cold 96% ethanol and processed for paraffin embedding as described previously (Brandtzaeg, 1974) . Sections cut at 6 gm were dewaxed and subjected to immunofluorescence staining at room temperature. One section from each series was stained by a trichrome routine method (HAS) containing haematoxylin, azofloxin and saffron (Stave & Brantzaeg, 1977) .
A murine monoclonal antibody to a nonpolymorphic human HLA-DR antigen (Beckton Dickinson, Sunnyvale, Calif., USA) was applied (1:20 for 20 h) in an indirect 3-step immunofluorescence method intensification, particularly apically in glandular structures. Both staining intensity and distribution area of staining were taken into account, each contributing about 50% of the sum. A score of 0 was given for virtually no staining: and 3 for intense overall fluorescence. 'Tumour score' was the mean score of all blocks from each tumour. The same investigator (S.N.A.) was responsible for the fluorescence scoring throughout the study; a blind test for both intra-and interobserver reproducibility was performed. For the interobserver test new sections were cut and immunostained. Proportions of agreement (P.) and Kappa values were estimated in the analysis of observer variability (Landis & Koch, 1977) .
The distribution of the DR was, in addition, separately categorised as heterogenous (extensive, intermediate or slight) or homogenous. An extensive degree of heterogenous staining refers to the presence of abrupt transition between positive and negative epithelium within the same crypt ). a b Figure 1 Moderately differentiated large bowel carcinoma. a, HAS staining (magnification x 20). b, Adjacent section stained green for HLA-DR determinants (magnification x 80).
All patients were followed until death or until June 1, 1992, with a mean of 11.4 years (range 10 to 14.3 years). Survival rates were computed by the actuarial or life-table method. Crude survival was based on all deaths; for corrected survival rates, deaths not due to cancer were censored at time of death. Information about recurrences and deaths due to cancer was obtained from the hospital records or the postmortem reports. The log-rank procedure was used to assess the statistical significance between survival distribution.
To estimate the effect of different factors on survival, a multivariate analysis was done by the proportional-hazards method proposed by Cox (1972) . Included in the analysis were the following factors: age, sex, clinicopathological stage, histologic grade, DNA ploidy pattern, DR staining, preoperative CEA plasma level, and tumour site.
Results
HLA-DR staining pattern, Dukes' stage, and histological grade When omitting the primary antibody or replacing it with an antibody of the same isotype (IgG2a), no staining was seen in adjacent sections from a tumour which stained positive with the anti-HLA-DR antibody.
Based on three samples, 52 tumours showed HLA-DR positivity in varying degrees ( Figure 1 ) and 48 were negative. There was some degree of intratumour variation; when evaluating only one section from each specimen, 38 were positive and 62 negative. Consequently, a mean score for each tumour was based upon the average of the scores from the three sections. The tumours were then divided into three groups according to the mean score: 0; 0.1-1.0; and >1.0.
There were no significant differences in HLA-DR score between tumours in each Dukes' stage (Table II) , whereas there were slightly more DR-positive tumours in the poorly differentiated group, compared to the better differentiated tumours (P = 0.04), (Table III) .
Concerning the heterogeneity of HLA-DR staining in the tumour, 39 of the tumours showed variable staining throughout the tumour tissue, whereas 61 showed a homogenous staining pattern, either positive (13) or negative (48). No difference in degree of heterogeneity was observed with regard to Dukes' stage, while there was a tendency for poorly differentiated carcinomas to be more homogenously stained (P = 0.04). Intraobserver reproducibility was 'substantial' (Kappa = 0.61) and interobserver (including repeated sectioning Chi square = 10.01; d.f. 6; P = 0.12.
and staining) reproducibility was 'moderate' (Kappa = 0.46) (Figure 2) , according to the classification by Landis and Koch (1977) .
Tumour HLA-DR expression and survival analysis
During the follow-up period there were 56 cancer specific deaths, whereas 12 patients died from other causes. Analysis of survival in the whole patient group showed significant differences between the three levels of tumour HLA-DR expression: 0; 0.1-1.0; > 1.0 (X2 = 10.214, d.f. = 2, P = 0.006), (Figure 3) . In a stratified analysis after Dukes' stages, there was still a significant difference (P <0.001) between the three levels of HLA-DR staining intensity (Figure 4) . Only one patient with tumour score for HLA-DR above 1.6 died from his cancer. This 73 year-old male patient, operated on for a rectal carcinoma, Dukes' stage B, survived for 6.8 years. Another male patient with a poorly differentiated Dukes'stage D rectal tumour with a HLA-DR score of 1.5, survived for 2.8 years.
According to the multivariate analysis, adjustment for other risk factors did not essentially change the estimate of the prognostic effect of HLA-DR expression on the relative risk for death from large bowel carcinoma (Table IV) .
3. (Valnes et al., 1984) . We are now comparing the alkaline phosphatase anti-alkaline phosphatase (APAAP) technique with the immunofluorescence method in a blind study.
In the present study, with a follow-up period of 10-14 years, 52% of the tumours showed positive staining for HLA-DR antigens in varying degrees. This is in agreement with previous studies which report detectable staining in about half of all colon carcinomas (Gutierrez et al., 1987; Degener et al., 1988; Ruiz-Cabello et al., 1988; Moller et al., 1991) .
In 39% of the tumours heterogenous staining was found, which is in accordance with Daar & Fabre (1983) . Heterogenous staining of HLA-DR in large bowel carcinomas has been claimed to be more common in well differentiated tumours, while the antigen expression becomes more homogeneous with decreasing degrees of differentiation . This would be in agreement with the clonal proliferation theory of tumour development proposed by Nowell (1976) . In the present study we could not find any relationship between heterogeneity and Dukes' stage. However, poorly differentiated tumours tend to be more often DR-positive and show a more homogeneous staining pattern. This finding in part confirms our previous suggestions .
Because of the significant prognostic impact, we think that staining for HLA-DR can profitably be included in the routine diagnostic procedure. Though the operation of scoring is a subjective exercise, our procedure showed good interand intraobserver reproducibility. Patients with negative tumours should then be followed up more closely and perhaps receive adjuvant therapy.
Our findings give support to the possibility of immunomodulation of tumours. The presence of HLA-DR on the surface membrane of the tumour cells is a prerequisite for activation of the CD 4 + T-cells and thereby release of cytokines, such as tumour necrosis factor-alpha (TNF) and 'y-interferon (INF). Induction of these determinants in clinically manifest carcinomas might help the patients' own immune system to inhibit further tumour growth. A human colonic carcinoma cell line which spontaneously synthesises surface HLA-DR has in vitro been stimulated to synthesise surface HLA-DR up to 19-fold when incubated in lymphocyte conditioned medium or with recombinant y-interferon (Lampert et al., 1985) . In another colonic carcinoma cell line TNF markedly and synergistically augmented INFinduced de novo synthesis of HLA-DR molecules (Kvale et al., 1988) , but TNF alone did not induce detectable levels of DR surface molecules. However, since treatment with TNF has failed to be of any effect in cancer patients (Rosenberg et al., 1989) , transfection of the TNF gene into tumourinfiltrating lymphocytes may turn out to be a better approach also in humans (Rosenberg, 1992) . Another possibility might be manipulation of the tumour cells by gene therapy. Enhanced expression of class II molecules on tumour cells can thus be achieved by transfected cytokine genes or by direct MHC gene transfection (James et al., 1991) . Recently a new gene therapy trial for malignant melanoma, injecting gene copies encased in liposomes into the tumour, has been commented on (Hoffman, 1992) . Our finding may suggest a similar approach in large bowel carcinoma by injection of gene copies into the tumour, encoding HLA-DR determinants which, displayed on the tumour cell surface, might trigger an immune response.
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